Wainwright Patrick, Byrne Christopher D
Clinical Biochemistry, University Hospital Southampton, Tremona Road, Southampton SO16 6YD, UK.
Nutrition and Metabolism, Faculty of Medicine, University of Southampton, Tremona Road, Southampton SO16 6YD, UK.
Int J Mol Sci. 2016 Mar 11;17(3):367. doi: 10.3390/ijms17030367.
Non-alcoholic fatty liver disease (NAFLD) represents a wide spectrum of liver disease from simple steatosis, to steatohepatitis, (both with and without liver fibrosis), cirrhosis and end-stage liver failure. NAFLD also increases the risk of hepatocellular carcinoma (HCC) and both HCC and end stage liver disease may markedly increase risk of liver-related mortality. NAFLD is increasing in prevalence and is presently the second most frequent indication for liver transplantation. As NAFLD is frequently associated with insulin resistance, central obesity, dyslipidaemia, hypertension and hyperglycaemia, NAFLD is often considered the hepatic manifestation of the metabolic syndrome. There is growing evidence that this relationship between NAFLD and metabolic syndrome is bidirectional, in that NAFLD can predispose to metabolic syndrome features, which can in turn exacerbate NAFLD or increase the risk of its development in those without a pre-existing diagnosis. Although the relationship between NAFLD and metabolic syndrome is frequently bidirectional, recently there has been much interest in genotype/phenotype relationships where there is a disconnect between the liver disease and metabolic syndrome features. Such potential examples of genotypes that are associated with a dissociation between liver disease and metabolic syndrome are patatin-like phospholipase domain-containing protein-3 (PNPLA3) (I148M) and transmembrane 6 superfamily member 2 protein (TM6SF2) (E167K) genotypes. This review will explore the bidirectional relationship between metabolic syndrome and NAFLD, and will also discuss recent insights from studies of PNPLA3 and TM6SF2 genotypes that may give insight into how and why metabolic syndrome features and liver disease are linked in NAFLD.
非酒精性脂肪性肝病(NAFLD)涵盖了一系列肝脏疾病,从单纯性脂肪变性到脂肪性肝炎(无论有无肝纤维化)、肝硬化和终末期肝衰竭。NAFLD还会增加肝细胞癌(HCC)的风险,而HCC和终末期肝病均可能显著增加肝脏相关死亡率。NAFLD的患病率正在上升,目前是肝移植的第二大常见适应症。由于NAFLD常与胰岛素抵抗、中心性肥胖、血脂异常、高血压和高血糖相关,因此NAFLD常被视为代谢综合征的肝脏表现。越来越多的证据表明,NAFLD与代谢综合征之间的这种关系是双向的,即NAFLD可导致代谢综合征特征,而这些特征反过来又会加重NAFLD或增加在无既往诊断者中发生NAFLD的风险。尽管NAFLD与代谢综合征之间的关系通常是双向的,但最近人们对基因型/表型关系产生了浓厚兴趣,即在肝脏疾病与代谢综合征特征之间存在脱节的情况。与肝脏疾病和代谢综合征分离相关的潜在基因型实例包括含patatin样磷脂酶结构域蛋白-3(PNPLA3)(I148M)和跨膜6超家族成员2蛋白(TM6SF2)(E167K)基因型。本综述将探讨代谢综合征与NAFLD之间的双向关系,还将讨论PNPLA3和TM6SF2基因型研究的最新见解,这些见解可能有助于深入了解代谢综合征特征与NAFLD中的肝脏疾病如何以及为何相关联。